Short-term outcomes of aflibercept biosimilar SB15 in macular edema secondary to retinal vein occlusion

Abstract Purpose To evaluate the short-term outcomes of SB15, an aflibercept biosimilar approved by the U.S. Food and Drug Administration, for the treatment of macular edema secondary to retinal vein occlusion (RVO). Methods This retrospective study included 29 treatment-naïve patients diagnosed wit...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Jaejin Cho, Sang Min Park, Chul Gu Kim, Jae Hui Kim
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	BMC 2026-03-01
Цуврал:	BMC Ophthalmology
Нөхцлүүд:	Aflibercept Biosimilar Macular edema Retinal vascular occlusion SB15
Онлайн хандалт:	https://doi.org/10.1186/s12886-026-04683-2
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!